Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy

JoAnn V. Pinkerton, MD,1 and James H. Pickar, MD2

Abstract
Objective: We review the historical regulation of drug compounding, concerns about widespread use of non-Food and Drug Administration (FDA)-approved compounded bioidentical hormone therapies (CBHTs), which do not have proper labeling and warnings, and anticipated impact of the 2013 Drug Quality and Security Act (DQSA) on compounding.

Methods: US government websites were searched for documents concerning drug compounding regulation and oversight from 1938 (passage of Federal Food, Drug, and Cosmetic Act [FDCA]) through 2014, including chronologies, Congressional testimony, FDA guidelines and enforcements, and reports. The FDCA and DQSA were reviewed. PubMed and Google were searched for articles on compounded drugs, including CBHT.

Results: Congress explicitly granted the FDA limited oversight of compounded drugs in a 1997 amendment to the FDCA, but the FDA has encountered obstacles in exercising that authority. After 64 patient deaths and 750 adversely affected patients from the 2012 meningitis outbreak due to contaminated compounded steroid injections, Congress passed the DQSA, authorizing the FDA to create a voluntary registration for facilities that manufacture and distribute sterile compounded drugs in bulk and reinforcing FDCA regulations for traditional compounding. Given history and current environment, concerns remain about CBHT product regulation and their lack of safety and efficacy data.

Conclusions: The DQSA and its reinforcement of §503A of the FDCA solidifies FDA authority to enforce FDCA provisions against compounders of CBHT. The new law may improve compliance and accreditation by the compounding industry; support state and FDA oversight; and prevent the distribution of misbranded, adulterated, or inconsistently compounded medications, and false and misleading claims, thus reducing public health risk.

Key Words: Bioidentical hormone therapy – Compounded drugs – Estrogen therapy – Menopause – Progesterone – Review.
2012, the International Academy of Compounding Pharmacists estimated that more than 25,000 US pharmacies engaged in basic drug compounding, at least 7,500 performed advanced (sterile) compounding, and approximately 3% of the 4 billion prescriptions filled annually in the United States were for compounded drugs. Custom-compounded bioidentical hormone therapy (CBHT), primarily consisting of estrogen and progesterone combinations, has grown tremendously. A recent study reported that up to 1 to 2.5 million US women use CBHT annually at an estimated annual cost of $1 to $2 billion.

Because compounded drugs like CBHT were custom-made for individual users by different pharmacies using different processes and ingredients, requiring compounders to evaluate the safety and efficacy of each unique formulation in clinical trials or to seek federal approval was considered impractical. Over the past few decades, however, drug compounding evolved beyond the local pharmacist to include manufacturers compounding medications in batches and shipping them across state lines. Legislators, regulators, healthcare professionals, and other stakeholders became concerned about the widespread use of unapproved medications—whether mass distributed or individually dispensed—that did not meet the same federal standards for efficacy, safety, and manufacturing as FDA-approved medications. After several safety incidents attributed to compounded drugs, culminating with 64 fatalities in 2012 from tainted methylprednisolone acetate injections compounded at a single facility, Congress passed the 2013 Drug Quality Security Act (DQSA). Title I of the DQSA (the Compounding Quality Act [CQA]) expands the FDA’s authority to regulate compounding facilities and reinforces its authority over traditional compounding under the Federal Food, Drug, and Cosmetics Act (FDCA).

This review article’s objectives are to provide historical context for enactment of the CQA, compare regulatory requirements for drug compounders versus manufacturers of FDA-approved drugs, and examine possible effects of the CQA on the drug compounding industry. We will also discuss safety and efficacy issues associated with CBHT and implications of the CQA for CBHT providers and users. Table 1 provides a glossary of abbreviations used in the review.

**SUMMARY OF THE GENERAL DRUG APPROVAL PROCESS**

The FDA requires pharmaceutical companies to establish the safety and efficacy of a drug candidate and seek approval of a drug before marketing it in the United States. The approval process for a new molecular entity is lengthy, rigorous, and expensive and typically begins with in vitro and animal testing to show the agent is active and unlikely to be toxic to humans. The sponsor then files an Investigational New Drug (IND) application explaining the preclinical findings and requesting permission to conduct human clinical trials.

Early clinical trials are typically designed to determine the drug’s pharmacokinetic properties and identify acute safety issues in a small number of healthy volunteers. Subsequent trials may test for dose response or provide preliminary data on efficacy and safety in the targeted population. Pivotal phase 3 trials are randomized controlled trials (RCTs) comparing the safety and efficacy of a new drug with placebo or another standard treatment and may recruit hundreds to thousands of participants. All study protocols must meet standards of the FDA and an Institutional Review Board or similar FDA-registered group.

The FDA has additional guidance specific to different drug classes or patient groups. The guidance for trials evaluating hormone therapy (HT) for indications of vasomotor symptoms (VMS) and vulvar vaginal atrophy (VVA) include specific eligibility criteria and safety and efficacy endpoints (Table 2).

**THE FDA’S EVOLVING APPROACH TO DRUG COMPOUNDING**

Compounding is the “combining, admixing, mixing, diluting, pooling, reconstituting, or otherwise altering of a drug or

---

**TABLE 1. Glossary of abbreviations**

| Abbreviation | Definition |
|--------------|------------|
| API          | Active product ingredients |
| CBHT         | Compounded bioidentical hormone therapy |
| CDER         | Center for Drug Evaluation and Research |
| CHT          | Compounded hormone therapy |
| CQA          | Compounding Quality Act (Title 1 of the DQSA) |
| DQSA         | Drug Quality Security Act (2013) |
| EPT          | Combined estrogen and progestogen therapy |
| FDA          | US Food and Drug Administration |
| FDAMA        | Food and Drug Administration Modernization Act (1997) |
| FDCA         | Federal Food, Drug, and Cosmetics Act (1938) |
| GMP          | Good Manufacturing Practices |
| HT           | Hormone therapy |
| IND          | Investigational New Drug |
| NDA          | New drug application |
| RCT          | Randomized controlled trials |
| SPB          | State pharmacy board |
| USP          | United States Pharmacopoeia |
| VMS          | Vasomotor symptoms |
| VVA          | Vulvar and vaginal atrophy |

---

Copyright © 2015 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.
bulk drug substance to create a drug.\textsuperscript{19} Makers of compounded drugs (including CBHT) who comply with appropriate FDCA provisions are exempt from the rigorous drug approval process established for branded drugs.\textsuperscript{20,22,29,30} Bioequivalency or pharmacokinetic studies are not required for compounded products.\textsuperscript{30,31} Makers of nonsterile compounded drugs who operate within FDCA restrictions for traditional compounding are generally exempt from GMP and routine FDA inspection.\textsuperscript{30,31} Thus, they have not been required to evaluate their customized drugs for purity, potency, or quality,\textsuperscript{30,32} although many may choose to self-monitor or be accredited by the Pharmacy Compounding Accreditation Board,\textsuperscript{33} a service of the Accreditation Commission for Health Care.\textsuperscript{34} Compounded medications can also be dispensed without standardized labels, use instructions, or product inserts.\textsuperscript{30,31} Whereas all FDA-approved HT products carry a boxed warning about the class-based risks of estrogens and progestogens, CBHT products—which contain these hormones—do not have this requirement.\textsuperscript{28}

**The FDCA**

The FDCA was passed in 1938 (Fig. 1) after 100 people died from strep-throat treatment (Elixir of Sulfanilamide), one of many tragedies over the years due to insufficient regulatory oversight of medicinal products.\textsuperscript{21} The FDCA fundamentally changed how drugs were developed and marketed in the United States. At the time it was enacted, drug compounding was considered an aspect of traditional pharmacy practice under state jurisdiction and the FDCA made no distinction between branded versus compounded drugs. However, the Act and its subsequent amendments endowed the FDA with broad authority to regulate all medical drugs and devices in the interest of protecting public health. Over the next 50 years,\textsuperscript{24} the FDA rarely enforced FDCA provisions against pharmacies engaged in compounding drugs that, as modified versions of FDA-approved products, were de facto unapproved new drugs. Instead, the FDA focused on compounders believed to pose a major threat to public safety and deferred to state pharmacy boards (SPBs) for policing compounders who committed less serious violations.\textsuperscript{35}

### TABLE 2. Safety and efficacy guidelines from the FDA for trials of hormone therapy\textsuperscript{27}

| Protocol recommendations | Efficacy considerations\textsuperscript{a} | Safety considerations |
|--------------------------|-------------------------------------------|----------------------|
| Dose-ranging studies prior to phase 3 development | Co-primary endpoint for VMS consists of mean changes at 4 and 12 weeks in Frequency of VMS Severity of VMS | Changes in lipid, carbohydrate, and coagulation parameters\textsuperscript{a} |
| \textgeq One randomized phase 3 trial Placebo-controlled Double-blind 12-Week duration Including ineffective dose | Co-primary endpoint for VVA consists of mean changes at 12 weeks in Most bothersome symptom Vaginal pH VMI (% change in parabasal and superficial cells) | Serum levels of parent compounds and metabolites New findings during physical examination, including breast changes Endometrial biopsy results for women with on-study uterine bleeding For EPT trials, 12-month incidence of\textsuperscript{b} Endometrial hyperplasia (target, <1%) Hyperplastic polyps and related atypia |

\textsuperscript{a}All changes are to be measured from baseline.

\textsuperscript{b}Slides must be evaluated separately by three independent pathology experts whose curricula vitae must be provided to the FDA.

---

**FIG. 1.** Timeline of regulatory actions and events related to drug compounding in the United States.
The FDA modernization act (§503A)

The FDA’s growing concern in the early 1990s that pharmacies “had begun producing drugs beyond what had historically been done with traditional compounding” and that “some pharmacists were manufacturing and selling drugs under the guise of compounding” to circumvent FDCA requirements, prompted the FDA to issue a Compliance Policy Guide in 1992 detailing plans for enforcing FDCA requirements against compounded drugs. The 1992 guidance was withdrawn after Congress passed the Food and Drug Administration Modernization Act (FDAMA) in 1997, codifying the FDA’s enforcement authority over compounding under the FDCA as §503A.

Under FDAMA, licensed pharmacists engaged in traditional compounding were exempted from GMP; federal labeling standards; and NDA requirements, including safety and efficacy studies, if their compounded drugs met certain requirements. They were not required to register with the FDA, undergo routine inspection, or report adverse events. To qualify for these exemptions, compounders could not advertise or solicit prescriptions for compounded drugs, regularly reproduce copies of FDA-approved drugs, or compound drugs the FDA classified as unsafe. Compounders had to use bulk substances or active product ingredients (APIs) for which a United States Pharmacopoeia (USP) or National Formulary monograph existed and were prohibited from making products the FDA considered too complex to produce in the pharmacy setting. In addition, FDAMA placed limits on a pharmacy’s out-of-state compounded drug sales. Although §503A formally codified and clarified the FDA’s authority to regulate compounding, primary oversight remained with state pharmacy boards (SPBs).

The compounding industry challenged FDAMA’s prohibitions on advertising and solicitation, and conflicting opinions from US courts left enforceability of FDAMA unclear. The Ninth Circuit Court of Appeals invalidated §503A in its entirety, whereas the US District Court of Nevada struck only the advertising provisions. The FDA appealed to the Supreme Court, which ruled in 2002 that the advertising restrictions were unconstitutional; however, the court did not address FDAMA’s remaining provisions. Months later, the FDA issued another Compliance Policy Guide on compounding, which led to further challenges to the FDA’s authority to regulate compounding and disparate rulings that left the FDA with varying levels of enforcement authority by region.

In 2005, Wyeth Pharmaceuticals, a maker of FDA-approved HT products, filed a Citizen Petition with the FDA to call attention to unregulated compounding practices. Wyeth alleged that several compounding pharmacies were violating provisions of §503A, such as copying FDA-approved HT products; making unsupported claims about CBHT’s safety and benefits, especially relative to FDA-approved HT; misbranding products; using unapproved hormones like estril; and failing to use GMP.

At a 2007 senate hearing on compounded drugs, then-director of the Center for Drug Evaluation and Research (CDER) Steven Galson acknowledged CBHT use was increasing and expressed concern that patients were being misled about CBHT’s benefits. He noted some compounders advertised CBHT products as superior to FDA-approved hormones despite the lack of scientific evidence and often neglected to inform patients and prescribers that approved and compounded HT likely carried similar risks. Between 2007 and 2008, the FDA issued warning letters to seven pharmacies making CBHT and launched a public awareness campaign to correct misperceptions about CBHT.

The CQA of 2013

The magnitude of risk to public health from unregulated compounded drugs became apparent in 2012 after contaminated methylprednisolone acetate injections compounded at the New England Compounding Center caused a multistate outbreak of meningitis. The final tally showed at least 13,500 patients in 20 states may have been exposed to the tainted steroid, resulting in 715 illnesses and 44 deaths.

During congressional hearings on the outbreak, FDA officials said the FDA was hampered in regulating compounders by “ambiguous, fragmented, unclear, and contested authorities in this particular realm of pharmacy and drug manufacturing.” Janet Woodcock of the CDER explained that because compounders did not have to register with the FDA, “We don’t know who they are, we don’t know where they are, and we don’t know what they are making.” Both officials told Congress the lack of mandatory reporting of adverse events associated with compounded drugs made it harder to identify potential health threats.

In November 2013, Congress passed the DQSA, which strengthens the FDA’s authority to regulate compounded pharmaceuticals under Title 1 (the CQA). The primary actions of the CQA are to add §503B to the FDCA, which defines outsourcing facilities as a new class of sterile drug compounders distinct from traditional compounders; and strike prohibitions on advertising and soliciting from §503A adjudicated as violating free speech, thus recodifying the FDA’s authority to regulate traditional compounding under FDAMA §503A. The CQA clarifies the applicability of misbranding provisions in the FDCA to include false and misleading claims about compounded drugs.

Outsourcing facilities are companies permitted to compound sterile drugs (ie, for intravenous, intramuscular, subcutaneous, intradermal, intrathecal, ophthalmic, otic, intranasal, or pulmonary administration) even without a prescription. Many are registered pharmacies that perform admixing and compounding of sterile drugs for hospitals. Traditional compounders are pharmacies that, as part of their practice, make customized medications prescribed for a patient with a medical need.

Table 3 summarizes how the amended FDCA applies to traditional compounders versus outsourcing facilities and compares this with regulatory requirements for manufacturers of FDA-approved drugs. Neither traditional compounders nor outsourcing facilities may compound drugs the FDA...
ALL COMPOUNDERS MUST USE COMPONENTS OF

Differences in federal regulations for drugs made by traditional compounders, registered outsourcing facilities, and commercial

Drugs must be

Otherwise, the FDA may seize

219

XX

NA

Compounders, like manu-

Com-

Registered facilities compliant with GMP and other

The CQA requires the FDA to develop

Although

The FDA

To encourage large-scale

Consideration

Must include drug name and “this is a compounded drug” on the label

Must package drugs with a label that accurately reports strength, quality, purity, and expiration

Must produce label name and “this is a compounded drug” on the label

Must adhere to GMPs

Must undergo federal inspection of the facility

Must report all transactions to the FDA every 6 mo

Must investigate and report adverse events

Must be a state-licensed pharmacist or physician

Production of compounded drugs requires a prescription

If not a licensed pharmacist or physician, must be supervised by one

Can only compound prescribed drugs for patients with a medical need

May sell drugs out of state

API, active product ingredient; FDA, Food and Drug Administration; GMP, Good Manufacturing Practices; NDA, New Drug Application; USP, United States Pharmacopoeia; X = required.

*Compounding facilities may compound approved drugs if a drug shortage has been confirmed.

**To be exempt from these provisions, a compounder must be compliant with the FDCA.

Traditional compounders do not have to follow GMPs but must prepare drugs in a sanitary fashion.

Traditional compounders may practice anticipatory compounding for a patient with a history of filling prescriptions for that drug at the facility.

Traditional compounders can fill a limited number of out-of-state prescriptions (typically <5%, depending on state law).

prices and shortages, or compound complex medications or dosage forms.

All compounders must use components of FDA-approved drugs or APIs or bulk drug substances for which a USP or National Formulary monograph exists or that are included on a forthcoming FDA list.

Drugs must be packaged correctly and accurately labeled with the drug’s strength, quality, and purity.

Compounders, like manufacturers of FDA-approved drugs, are barred from making false or misleading claims about their products.

Because the law does not establish a nationwide tracking system for drug compounders, the FDA will largely depend on SPBs for notification of compounders who are not registered outsourcing facilities and are noncompliant with §503A.

The CQA requires the FDA to develop an electronic system to receive SPB communications.

The FDA plans to prioritize enforcement of compounding based on risk, devoting more resources to pharmacies with a history of unsafe sterile compounding.

Although the CQA is expected to improve the safety of some compounded drugs, it is not intended to hold compounded drugs to the same safety and efficacy standards as FDA-approved drugs.

OUTSOURCING FACILITIES

Under the CQA, compounders who plan to continue making sterile medications without prescriptions may voluntarily register with the FDA as an outsourcing facility. Although

The FDA inspects outsourcing facilities at registration and on a risk-needed basis thereafter for GMP compliance.

Although outsourcing facilities do not have to be licensed pharmacies, a licensed pharmacist or physician must supervise compounding.

Registered facilities compliant with GMP and other CQA provisions may ship unlimited quantities of compounded drugs across state lines. They will remain exempt from having to meet strict labeling requirements, conducting safety and efficacy trials, and submitting products for FDA approval. They must regularly report all transactions and serious, unexpected adverse events to the FDA.

Compliers who do not qualify as traditional compounders under §503A yet decline to register as an outsourcing facility under §503B will be regarded as commercial drug manufacturers and are expected to file an IND application for any drug noncompliant with §503A. Otherwise, the FDA may seize their products or issue injunctions. To encourage large-scale compounders of sterile drugs to register, the FDA is urging hospitals and other drug purchasers to adopt policies requiring sterile compounded drugs to be purchased from registered outsourcing facilities.

TRADITIONAL DRUG COMPOUNDERS

Physicians and pharmacists who practice traditional compounding and wish to remain exempt from FDA approval requirements for new drugs, GMP, and labeling requirements for safe use must meet conditions laid out in §503A. They require licenses and can only compound medications “based on the receipt of a valid prescription order, or a notation,
approved by the prescribing practitioner, on the prescription order that a compounded product is necessary for the identified patient. Traditional compounders are permitted to compound “limited quantities” of medications for prescriptions for established patients.

In July 2014, the FDA issued guidance for traditional compounders that limits their interstate transactions to 5% or less of total prescriptions unless the FDA has a memorandum of understanding with the compounding pharmacy’s state. The SPBs will retain primary responsibility for regulating traditional compounding. However, should the FDA determine a compounded drug violates §503A, possible penalties include warning letters, product seizures, injunctions, or prosecution. The extent to which reinstatement of §503A will affect traditional compounding is expected to become clearer once the FDA publishes its final lists of bulk drug substances, drugs that present demonstrable difficulty in compounding, and unsafe or ineffective drugs not permitted to be compounded.

SAFETY AND QUALITY CONCERNS WITH COMPOUNDED DRUGS

Since the 2012 meningitis outbreak, the FDA has documented 20 compounders who shipped contaminated drugs, 125 patients who experienced serious adverse events, and more than 150 compounded products recalled because of contamination. Of the more than 60 sterile compounding facilities the FDA inspected, almost none were GMP compliant. Reported violations include failure to maintain sanitary conditions, failure to conduct endotoxin and sterility tests or calibrate equipment, and storing expired and unexpired products together.

According to Staes et al, sterile compounded products contaminated with microorganisms caused at least 11 outbreaks between 2000 and 2012 (excluding the 2012 meningitis outbreak). These other outbreaks resulted in 207 infections and 17 deaths due to causes such as meningitis, septic arthritis, bloodstream infections, endophthalmitis, and systemic inflammatory response syndrome.

Potency is another concern with compounded drugs. Several studies comparing the potency of compounded drugs with their FDA-approved counterparts found a high percentage of compounded samples had API amounts much lower or higher than stated. Stark variations in potency were identified between multiple samples of the same compounded product. In contrast, potency for almost all FDA-approved products fell within FDA guidelines, which was consistent with an FDA statement that less than 2% of FDA-approved drugs fail routine potency testing.

In 2001, the FDA evaluated 29 sterile and nonsterile compounded products from 12 pharmacies. Although no drug failed purity testing, 31% (nine of 29) were subpotent, containing 59% to 89% of the reported API. In 2006, the FDA conducted a similar study of 125 APIs and 36 mostly nonsterile compounded drugs, showing 33% (12/36) were subpotent or superpotent, including nine (30%) of 31 CBHT products. The noncompliant products contained 68% to 268% of the expected API. Some CBHT capsules that contained multiple estrogens were simultaneously subpotent and superpotent within the same finished product sample. Figure 2 illustrates an example of a finished product in which capsules contained estradiol, estradiol, and estrone, wherein the concentrations of each of these estrogens varied from subpotent to superpotent among the capsules (Fig. 2). Each year, the Missouri SPB assesses a sample of drugs compounded at Missouri pharmacies. In 2013, the API for 13% of 112 products analyzed ranged from 3% to 227% of the labeled amount. Of the seven drugs that failed, three were CBHTs. All failed CBHT products were oral capsules: one containing estradiol, estradiol, and progesterone; one with estradiol, estradiol, progesterone, and dehydroepiandrosterone; and the last one delivering estradiol, estradiol, and testosterone.

The writer of an award-winning investigative report for More magazine filled 12 prescriptions for capsules containing Tri-Est and progesterone at compounding pharmacies in various states and had them analyzed at Flora Research Laboratories in Oregon. Capsules differed in weight (range, 80-102 mg) and potency relative to the labeled doses of estradiol (range, 67.5%-89.5%), estrone (range, 58.4%-272.5%), and estradiol (range, 95.9%-259%). Most capsules contained ~80% of progesterone prescribed, and none met FDA potency requirements. Although these data do not carry the weight of a formal scientific study, they raise concern as to whether women taking CBHT are receiving the doses prescribed.

Compounding errors resulting in superpotent doses may increase the risk of overdose or intensify adverse effects, whereas subpotent doses may not contain sufficient API to treat the condition for which they were prescribed. Combined CBHT products that contain more estrogen and/or less progesterone than prescribed could fail to provide the right ratio of hormones to protect the endometrium. Increased amounts of estrogen or progesterone could also increase venous thromboembolism risk or breast stimulation.

FIG. 2. Analysis of the content of individual capsules for the potency of three estrogens within a single sample of a compounded drug. The x axis shows categories of number of capsules with each ingredient amount. Dashed lines represent 10% variation from the amount of drug declared on the product labeling. Shaded symbols fall outside of the 10% variation line.
**Additional concerns regarding CBHT**

Various CBHT formulations containing estrogens, progesterone, or testosterone are marketed to women with menopausal symptoms in nonsterile (eg, lotions, creams, capsules, lozenges, transdermal patches, nasal or oral products, and suppositories) and sterile (eg, injections and subdermal pellets) preparations. Some CBHT medications fall into product categories the FDA considers “not appropriate for compounding under any circumstances,” including extended-release, transdermal, and liposomal drugs.2

The FDA has never approved testosterone for postmenopausal women, and its use in CBHT regimens is controversial.41,61 Estriol is found in many CBHT products, including Bi-Est (20% estradiol and 80% estriol) and Tri-Est (10% estradiol, 10% estrone, and 80% estriol). Although an estriol vaginal suppository is approved to treat vaginal atrophy in some countries,61 estriol is not in any FDA-approved drug for human use, and the FDA has warned compounders not to use estriol without filing an NDA.41,50,62,63 However, a USP monograph exists for estriol, and §503A permits compounders to use active ingredients that have a USP monograph.30,31

Randomized controlled trials have proven that progesterone inhibits estrogen stimulation of the endometrium.64,65 Administering progesterone orally or transdermally at a high enough dose to ensure sufficient bioavailability is challenging.66,67 Many CBHT regimens incorporate nonoral progesterone, yet no adequate RCTs have established any delivery method of progesterone besides oral as effective or capable of protecting the endometrium from estrogen’s effects.7,32,60,68

Underdosing of progesterone in an EPT regimen may increase the risk of endometrial cancer.32,64 Cases have been published of postmenopausal women who developed irregular vaginal bleeding and were later found to have endometrial cancer after taking CBHT containing estrogen and progesterone for several years.64,69

The peer-reviewed literature contains no reports of adequate phase 3 trials that have proven CBHT is safe and effective, and none of the published studies on CBHT satisfy FDA guidance for clinical trials to demonstrate the safety and efficacy of a drug. Most included small sample sizes, were poorly designed, or compared unequal doses; few evaluated endometrial safety after 1 year of use.70,76

Authors of a systematic literature search for RCTs evaluating compounded progesterone cream for vasomotor symptoms found three RCTs, none of which applied the FDA methodology for assessing endometrial safety.76 A few observational studies and surveys offered low-level evidence that CBHT improved menopausal symptoms, but most consolidated results for all CBHT used, ignoring differences in hormones, doses, and delivery methods.60,73-75,77

**GUIDELINES FOR CBHT**

The Endocrine Society, The North American Menopause Society, American Congress of Obstetricians and Gynecologists, American Society for Reproductive Medicine, and International Menopause Society recommend against CBHT use by anyone without a medical condition preventing them from using FDA-approved HT.32,62,70,78-80 The FDA has also issued caution against compounded drug use.41 Concerns include inadequate evidence of efficacy and safety, variable purity and potency, and insufficient labeling.32,62,70,78-80 The FDA made a statement about CBHT (2008): “FDA is concerned that the claims for safety, effectiveness, and superiority that these pharmacy operations are making mislead patients, as well as doctors and other healthcare professionals. Compounded drugs are not reviewed by the FDA for safety and effectiveness. Patients who use compounded hormone drugs should discuss menopausal HT options with their healthcare provider to determine whether compounded drugs are the best option for their specific medical needs.”

Some CBHT prescribers use salivary or serum testing of hormone levels for titration,81,82 but these tests are considered meaningless without pharmacokinetic data.32 and no RCT has correlated hormone levels in saliva or serum with outcomes. An FDA statement on saliva testing to titrate CBHT says, “Hormone levels in saliva do not accurately reflect the amount of hormones a woman has in her body for the purpose of adjusting hormone therapy dose levels. A woman’s hormone levels change throughout the day and from day to day.”82 None of the major menopause societies recommend using salivary testing to guide treatment81,82; their treatment guidelines advise to prescribe the lowest effective dose of FDA-approved HT for menopausal symptom relief.32,62,83,84

**CONCLUSIONS**

To gain approval, makers of FDA-approved products must conduct extensive testing to prove a drug is effective and safe for human use and follow strict standards for manufacturing. For HT intended-to-treat menopausal symptoms, the FDA provides specific guidance for clinical trial evaluation. Thus, FDA-approved therapies have documented safety and efficacy unlike CBHT products, which have not been rigorously tested. The FDA recommends using an approved drug over a compounded one when possible, due to their concerns about safety, efficacy and misbranding, but recognizes that some patients may need a compounded drug when no FDA-approved drug is available to meet their needs.13 The CQA adds §503B and makes clear that §503A now applies throughout the country, removing previous obstacles and impediments to both SPB and FDA enforcement. The new law may improve compliance, accreditation, and monitoring by the compounding industry, support oversight by states and the FDA, and prevent the distribution of misbranded, adulterated, or inconsistently compounded medications, thus reducing the risk to public health.

**Acknowledgments:** We would like to acknowledge Sebastian Mirkin, MD, of TherapeuticsMD and Sarah Sellers, PharmD, MPH, for their assistance in reviewing the manuscript; and Christin Melton, ELS, CMPP, at Precise Publications, LLC, for providing medical writing support and assisting in compiling and reviewing FDA documents.

---

Copyright © 2015 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.
REFERENCES

1. US Government Accountability Office. Drug Compounding: Clear Authority and More Reliable Data Needed to Strengthen FDA Oversight. Washington, DC: US Government Accountability Office; 2013. GAO publication 13-702.

2. Hearing Before the House of Representatives Subcommittee on Health of the Committee on Energy and Commerce, 113th Cong, 1st Sess (July 16, 2013) (statement of Janet Woodcock, MD, director, CDER, FDA).

3. Media briefing on implementation of the Drug Quality and Security Act [transcript]. US Food and Drug Administration Website. Available at: http://www.fda.gov/downloads/NewsEvents/Newroom/Mediacr:

4. International Academy of Compounding Pharmacists. The International Academy of Compounding Pharmacists responds to meningitis outbreak tied to compounding pharmacy [news release]. Available at: http://cymeld.com/sites/www.iacpxr.org/resources/resmgr/imported/IACP%038;0%20Responds%20to%20Meningitis%20Outbreak%20Release%20October%202012.pdf. Accessed June 20, 2014.

5. The Henry J. Kaiser Family Foundation. Total number of retail prescription drugs filled at pharmacies. Available at: http://kff.org/other/state-indicator/total-retail-rx-drugs. Accessed June 20, 2014.

6. Pinkerton JV, Santoro N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause 2015;22:926-936.

7. The North American Menopause Society. Bioidentical hormone therapy: custom-compounded vs government-approved. Available at: http://www.menopause.org/docs/for-women/nmbioidenticals.pdf. Accessed April 2014.

8. Examining Drug Compounding. House of Representatives hearing before the Subcommittee on Health of the Committee of Energy and Commerce, 113th Cong, 1st Sess (May 23, 2013) (statement of Janet Woodcock, MD, director, CDER, FDA).

9. Hearing Before the Senate Committee on Health, Education, Labor, and Pensions, 108th Cong, 1st Sess (July 17, 2003) (testimony of Steven K.Galson, MD, acting director, CDER, FDA).

10. Hearing Before the Senate Committee on Health, Education, Labor, and Pensions, 112th Cong, 2nd Sess (November 15, 2012) (statement of Margaret A.Hamburg, MD, commissioner, FDA).

11. Hearing Before the House of Representatives Subcommittee on the Health of the Committee on Energy and Commerce, 113th Cong, 1st Sess (May 23, 2013) (statement of Janet Woodcock, MD, director, CDER, FDA).

12. Hearing Before the Senate Committee on Health, Education, Labor, and Pensions, 112th Cong, 1st Sess (October 23, 2003) (testimony of Steven K.Galson, MD, acting director, CDER, FDA).

13. Florida Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms—recommendations for clinical evaluation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075090.pdf. Accessed December 9, 2014.

14. Information concerning outsourcing facility registration. US Food and Drug Administration Website. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/OutsourcingFacilities/ucm075918.htm. Accessed June 3, 2014.

15. Federal Food, Drug, and Cosmetic Act, 21 USC §301, (2006).

16. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance: compounding of human drug products under Section 503A of the Federal Food, Drug, and Cosmetic Act. Available at: http://www.fda.gov/downloads/drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm377052.pdf. Accessed April 5, 2013.

17. Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee. Committee opinion no. 532: compounded bioidentical menopausal hormone therapy. Obstet Gynecol 2012;120:411-415.

18. Pharmacy Compounding Accreditation Board: For Pharmacists. Available at: http://achc.org/pcab. Accessed March 4, 2015.

19. ACHC Pharmacy Accreditation. Available at: http://achc.org/programs/pharmacy. Accessed March 4, 2015.

20. Thompson v Western States Medical Center, 535 US 357, (2002).

21. Guidance for FDA Staff and Industry, Compliance Policy Guides Manual. Sec. 460.200 Pharmacy Compounding. US Food and Drug Administration Website. Available at: http://www.fda.gov/ohrms/dockets/dockets/05p0411/05p-0411-cp00001-01-vol1.pdf. Accessed April 10, 2014.
59. Musshoff F, Madea B, Woelfle J, et al. Xylometazoline poisoning: a 56. Chollet JL, Jozwiakowski MJ. Quality investigation of hydroxyprogesterone 55. Hermann AC, Nafziger AN, Victory J, et al. Over-the-counter progesterone 54. Green DM, Jones AC, Brain KR. Content variability of active drug 53. Mahaguna V, McDermott JM, Zhang F, et al. Investigation of product 52. Azarnoff DL, Lee JC, Lee C, et al. Quality of extemporaneously com- 51. FDA 483 inspection report, Abrams Royal Pharmacy. US Food and Drug 49. Compounding: inspections, recalls, and other actions. US Food and Drug 48. Hearing Before the House of Representatives Subcommittee on Agriculture, 47. Department of Health and Human Services. Fiscal year 2015 budget for the US Food and Drug Administration. Justification of estimates for appropriations committees. Available at: http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/BudgetReports/UCM336309.pdf. Accessed April 10, 2014.

54. Green DM, Jones AC, Brain KR. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharmacol Ther 2012;37:53-57.
55. Hermann AC, Nafziger AN, Victory J, et al. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved progesterone product. J Clin Pharmacol 2005;45:614-619.
56. Chollet JL, Jozwiakowski MJ. Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection. Drug Dev Ind Pharm 2012;38:540-549.
57. Missouri Board of Pharmacy. Annual Report FY 2013. Available at: http://pr.mo.gov/boards/pharmacy/annualreports/2013%20Annual%20 Report.pdf. Accessed March 25, 2015.
58. Ramin CJ. The hormone hoax thousands fall for. Available at: http:// fj.org/fj/website/wp-content/uploads/2013/09/MORE.pdf. Accessed April 14, 2014.
59. Musshoff F, Madea B, Woelfle J, et al. Xylometazoline poisoning: a 40-fold nasal overdose caused by a compelling error in 3 children. Forensic Sci Int 2014;238:e3-e5.
60. Ruiz AD, Daniels KR. The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in post-menopausal women: an observational cohort study. Int J Pharm Compd 2014;18:70-77.

61. Conaway E. Bioidentical hormones: an evidence-based review for primary care providers. J Am Osteopath Assoc 2011;111:153-164.
62. The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
63.Warning letter to Village Compounding Pharmacy. US Food and Drug Administration Website. Available at: http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048444.htm. Accessed April 10, 2014.
64. Davis R, Batur P, Thacker HL. Risks and effectiveness of compounded bioidentical hormone therapy: a case series. J Womens Health (Larchmt) 2014;23:642-648.
65. Du JY, Sanchez P, Kim L, et al. Percutaneous progesterone delivery via cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood. Menopause 2013;20:1169-1175.
66. Wren BG, Champion SM, Willetts K, et al. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003;10:13-18.
67. Zargar-Shoshtari S, Wahhabaghei S, Mehrsai A, et al. Transdermal delivery of bioidentical progesterone using dutasteride (A 5alpha-reductase inhibitor): a pilot study. J Pharm Pharm Sci 2010;13:626-636.
68. Pinkerton JV. The truth about bioidentical hormone therapy. Female Patient 2012;37:16-20.
69. Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with “bioidentical” hormone replacement therapy. Med J Aust 2007;187:244-245.
70. Moyer VA, U.S.Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:47-54.
71. Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004;11:356-367.
72. Boudeaux’s New Drug Store. Introduction to: compounded bio-identical hormone replacement [patient handout]. Available at: http://boudeauxs-newdrug.com/files/2015/01/BNDS-Intro-to-BHRT-2013.pdf. Accessed April 14, 2014.
73. Vigezza KA, Downhour NP, Chiu MA, Cappellini L, Musil JD, McCal- lain DJ. Efficacy and tolerability of compounded bioidentical hormone replacement therapy. Int J Pharm Compd 2004;8:313-319.
74. Ruiz AD, Daniels KR, Barner JC, et al. Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study. BMC Womens Health 2011;11:27.
75. Mahmud K. Natural hormone therapy for menopause. Gynecol Endo- crinol 2010;26:81-85.
76. Whelan AM, Jurgens TM, Trinacty M. Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective? Ann Pharma- macother 2013;47:112-116.
77. Spark MJ, Willis J, Byrne G. Compounded progesterone: why is it acceptable to Australian women? Maturitas 2012;73:318-324.
78. Australian Menopause Society. Bioidentical hormones for menopausal symptoms. Available at: http://www.menopause.org.au/consumers/infor mation-sheets/34-bioidentical-hormones-for-menopausal-symptoms. Accessed April 10, 2014.
79. Panay N, Hamoda H, Aya R, et al. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int 2013;19:59-68.
80. The Endocrine Society Position Statement. Bioidal hormones. Available at: https://www.endocrine.org/~media/endocrineFiles/Ad vocacy%20and%20Outreach/Position%20Statements/All/BH_Position_ Statement_final_10_25_06_w_Head.pdf. Accessed April 11, 2014.
81. Cirigliano M. Bioidal hormone therapy: a review of the evidence. J Womens Health 2007;16:600-631.
82. Bio-identicals: sorting myths from facts. US Food and Drug Adminis- tration Website. Available at: http://www.fda.gov/ForConsumers/Con sumerUpdates/ucm09311.htm. Accessed April 14, 2014.
83. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause 2013;20: 888-902.
84. De Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013; 16:316-337.